Skip to content
Friday 7 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

Mounjaro

  • Mounjaro sales help almost double Ely Lilly’s UK turnover

    The sale of weight loss drug Mounjaro has boosted the UK turnover of pharmaceuticals giant Eli Lilly by 90 per cent during its latest financial year, it has been revealed. The division of the US group has posted a turnover of £889m for 2024, according to new accounts filed with Companies House. The new total [...]

    UK profit at Eli Lilly has also been boosted because of the sale of Mounjaro. (Photo by Scott Olson/Getty Images)
  • Ozempic sales surge as priced-out Mounjaro patients seek cheaper alternative

    healthcare

    Ozempic sales have risen five-fold after a 126 per cent rise in the price of the Mounjaro drug due to pressure from US President Donald Trump.  Mounjaro, manufactured by U.S. pharma giant Eli Lilly, has been the UK’s most popular weight loss jab, prescribed to an estimated 90 per cent of the country’s patients.  But around [...]

    Four in 100 households in the UK now have at least one member using GLP-1, the active ingredient in weight-loss drugs like Ozempic.
  • Mounjaro and Wegovy demand helps Chemist4U sales double

    healthcare

    Increasing demand for weight-loss jabs such as Mounjaro and Wegovy has helped sales at the firm behind online pharmacy Chemist4U almost double. The Skelmersdale-based business has reported a turnover of £59.5m for the year to 30 September, 2024, according to new accounts filed with Companies House. The latest total comes after the firm behind Chemist4U [...]

    Sales at the company behind Chemist4U have doubled thanks to the demand for weight-loss drugs. (Photo Illustration by Scott Olson/Getty Images)
  • Is your business about to feel the Ozempic squeeze? 

    November 4, 2024

    Reshaping stomachs with weightloss drugs like Ozempic likely means reshaping some markets (and probably your strategy), says Paul Armstrong Ozempic, Wegovy, and Mounjaro are driving a subtle but undeniable shift in obesity rates across the U.S, showing a 2 per cent drop so far. While it’s too soon to crown these drugs the cure-all, their [...]

Trending Articles

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Rupert Lowe axes pensions triple lock and pledges tax cuts in economic plan

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • As it happened: Stocks rise as oil fluctuates after Red Sea attack; US-Iran deal ‘being circulated’

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook